Class Action Alert for APLT Shareholders
The Gross Law Firm is reaching out to shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT) with significant news regarding a class action lawsuit. This lawsuit may provide an opportunity for investors affected by recent developments to seek justice and recover losses sustained during the designated class period.
Understanding the Class Period
Shareholders who purchased shares of APLT from early January 2024 to early December 2024 are especially encouraged to come forward. This period witnessed tumultuous challenges for Applied Therapeutics, leading to drastic shifts in the stock price that directly impacted investors.
The Allegations Against Applied Therapeutics
On November 27, 2024, Applied Therapeutics made an announcement that reverberated through the market: they received a Complete Response Letter (CRL) concerning their New Drug Application (NDA) for the drug candidate, govorestat. The FDA highlighted deficiencies in the clinical data, which raised serious concerns about the company’s compliance and clinical trial processes.
Following this revelation, there was a significant and alarming decline in the stock price of Applied Therapeutics. After closing at **$10.21** on November 26, 2024, the stock plummeted, closing at **$8.57** the next day. The downward trend continued, with shares dropping to **$2.03** by November 29, 2024, and ultimately reaching **$1.75** by December 2, 2024 — a staggering over 80% loss.
The FDA’s Warning Letter
Moreover, on December 2, 2024, after the market had closed, the company disclosed that it received a warning letter from the FDA. This letter referenced serious issues related to its clinical trials, compounding the fallout from the CRL. Post-announcement, shares fell further to **$1.69** on December 3, **$1.38** on December 4, and **$1.29** on December 5, reinforcing the gravity of the situation.
Important Registration Deadline
As the situation develops, shareholders should not hesitate to register for this class action. The **deadline for registering** is **February 18, 2025**. Those who register will gain access to portfolio monitoring software, which will keep them updated on the case's progress. Remember, you do not need to become a lead plaintiff to participate in the recovery effort.
Why Engage with The Gross Law Firm?
The Gross Law Firm is dedicated to advocating for investors who have suffered losses due to misleading or deceitful corporate actions. Their mission is to ensure that companies uphold ethical business practices while protecting shareholders' rights. They strive for accountability when companies fail to provide accurate, material information, leading to unjustifiable inflation of stock prices.
How to Contact The Gross Law Firm
If you believe you are a shareholder affected by the events surrounding APLT, contacting The Gross Law Firm is a crucial step. They are positioned to assist you in navigating this complex legal landscape. You can reach them at:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the purpose of this class action lawsuit?
This class action lawsuit aims to represent shareholders of Applied Therapeutics who experienced financial losses due to alleged misleading statements made by the company.
When is the deadline for shareholders to register?
The deadline for shareholders to register for this class action is February 18, 2025.
What losses can shareholders potentially recover?
Shareholders may potentially recover losses sustained due to the decline in APLT's stock price related to the disclosures made by the company regarding their drug application.
Do shareholders need to be lead plaintiffs to participate?
No, shareholders do not need to be appointed as lead plaintiffs to partake in any recovery from the class action.
How can I stay updated on the case?
Upon registration, shareholders will receive updates through portfolio monitoring software that provides current status on the case.
